# The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

> **NCT06160362** · NA · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Non-hodgkin Lymphoma,B Cell

## Interventions

- **BIOLOGICAL:** CART-19 and 20 cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06160362
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-31
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06160362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06160362, "The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06160362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*